EICHOR
● Not Yet Recruiting
A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH.
Condition: Paroxysmal Nocturnal Hemoglobinuria · Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
About this study
An open label study to evaluate the efficacy and safety of FXS6837 capsules compared to eculizumab in naive PNH patients. About 90 PNH patients who are naive to complement inhibitor therapies will be enrolled to take FXS6837 capsules or eculizumab for 24 weeks according to protocol.
This description comes directly from the study's public registry record.
Talk to the study team
Rong Fu · +86 13920350233 · furong8369@tmu.edu.cn
Hui Liu · +86 13821113189 · liuhui8003@qq.com
Always discuss trial participation with your own doctor first.
Locations (1)
| TianJin Medical University General Hospital | Tianjin, Tianjin Municipality, China | — |
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07747090